Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 7OTHER_GOV 2NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Cancer Pain 2Wounds and Injuries 1Head and Neck Neoplasms 1Breast Neoplasms 1Agnosia 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Morphine × Clear all
NCT05800834 2023-09-28

MorphineGEL

Instituto Nacional de Cancer, Brazil

Phase 2 Unknown
106 enrolled
BreastHead & Neck

Cancer Pain, Breast Neoplasms, Head and Neck Neoplasms, Wounds and Injuries

NCT04243954 2021-03-05

Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration

Fujian Cancer Hospital

Phase 2 Completed
95 enrolled

Cancer Pain, Agnosia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡